Abstract: The disclosure concerns a method for measuring and reporting vascularity in a biological tissue sample. The method generally includes: within a digital image of a tissue section, (i) identifying endothelial cells, lymphatic cells, or a combination thereof; (ii) mapping one or more proximity regions, each of the proximity regions defining an area between detected vessels and a first distance outwardly therefrom; and (iii) calculating one or more of: a vessel proximity score or a hypoxia score, wherein the vessel proximity score relates a composition of objects within the proximity regions, and wherein the hypoxia score relates a composition of tissue within or outside of the proximity regions, respectively.

Abstract: The disclosure concerns a method for measuring and reporting vascularity in a biological tissue sample. The method generally includes: within a digital image of a tissue section, (i) identifying endothelial cells, lymphatic cells, or a combination thereof; (ii) mapping one or more proximity regions, each of the proximity regions defining an area between detected vessels and a first distance outwardly therefrom; and (iii) calculating one or more of: a vessel proximity score or a hypoxia score, wherein the vessel proximity score relates a composition of objects within the proximity regions, and wherein the hypoxia score relates a composition of tissue within or outside of the proximity regions, respectively.

Abstract: The instant disclosure describes a method for measuring and reporting vascularity in a biological tissue sample. The method generally includes: within a digital image of a tissue section, (i) identifying endothelial cells, lymphatic cells, or a combination thereof; (ii) mapping one or more proximity regions, each of the proximity regions defining an area between detected vessels and a first distance outwardly therefrom; and (iii) calculating one or more of: a vessel proximity score or a hypoxia score, wherein the vessel proximity score relates a composition of objects within the proximity regions, and wherein the hypoxia score relates a composition of tissue within or outside of the proximity regions, respectively.

Abstract: The present invention provides methods of determining the size of a particular nucleic acid segment of interest in a sample of nucleic acids through fragmentation of DNA, size fractionation, an optional second fragmentation, and identification using a marker sequence. In particular aspects, an expansion or reduction of tandem repeat sequences can be detected. In further aspects, carriers and individuals afflicted with fragile X syndrome or other diseases associated with tandem repeats can be distinguished from normal individuals.

Abstract: The present invention provides methods of determining the size of a particular nucleic acid segment of interest in a sample of nucleic acids through fragmentation of DNA, size fractionation, an optional second fragmentation, and identification using a marker sequence. In particular aspects, an expansion or reduction of tandem repeat sequences can be detected. In further aspects, carriers and individuals afflicted with fragile X syndrome or other diseases associated with tandem repeats can be distinguished from normal individuals.

Abstract: The present invention provides methods of determining the size of a particular nucleic acid segment of interest in a sample of nucleic acids through fragmentation of DNA, size fractionation, an optional second fragmentation, and identification using a marker sequence. In particular aspects, an expansion or reduction of tandem repeat sequences can be detected. In further aspects, carriers and individuals afflicted with fragile X syndrome or other diseases associated with tandem repeats can be distinguished from normal individuals.

Abstract: The present invention provides methods for the diagnosis of a disease or condition in an individual. The methods employ a primary self-organizing map trained with biological marker profiles from tissues having known diseases or conditions, in combination with a secondary self-organizing map which displays a representation of a subset of the primary self-organizing map with sample data obtained from an individual in need of diagnosis. A result is prepared from the secondary SOM(s) that reveals the extent of similarity between the known diseases or conditions with the sample data set of the individual. The result can be provided to a practitioner to aid in the diagnosis of the individual.

Abstract: The present invention provides methods for the diagnosis of a disease or condition in an individual. The methods employ a primary self-organizing map trained with biological marker profiles from tissues having known diseases or conditions, in combination with a secondary self-organizing map which displays a representation of a subset of the primary self-organizing map with sample data obtained from an individual in need of diagnosis. A result is prepared from the secondary SOM(s) that reveals the extent of similarity between the known diseases or conditions with the sample data set of the individual. The result can be provided to a practitioner to aid in the diagnosis or prognosis of the individual. The result can additionally be used to select an individual for a clinical trial to evaluate a treatment.

Abstract: The present invention provides methods of determining the size of a particular nucleic acid segment of interest in a sample of nucleic acids through fragmentation of DNA, size fractionation, an optional second fragmentation, and identification using a marker sequence. In particular aspects, an expansion or reduction of tandem repeat sequences can be detected. In further aspects, carriers and individuals afflicted with fragile X syndrome or other diseases associated with tandem repeats can be distinguished from normal individuals.

Abstract: This invention provides novel methods for the detection of chitinous contaminants of non-chitinous biological materials. The methods are accurate, highly reproducible, rapid and relatively inexpensive. The methods are well suited to commercial applications, particularly in the food and agriculture industry where biological materials (e.g. food products) are regularly screened for contaminants (e.g. insect, mold, fungus, etc.). In one embodiment, the methods involve contacting a biological sample with a probe that is a lectin that binds chitin, contacting the sample with a pectinase; and detecting binding of said lectin to a chitin where the binding indicates the presence of chitin in the biological sample.

Abstract: Methods for the detection of chitinous contaminants of non-chitinous biological materials are described. The methods are accurate, highly reproducible, rapid and relatively inexpensive. The methods are well suited to commercial applications, particular in the food and agriculture industry where biological materials (e.g., food products) are regularly screened for contaminants (e.g., insect, mold, fungus, etc.). In some cases, the methods involve contacting a biological sample with a probe that is a lectin that binds chitin, contacting the sample with a pectinase; and detecting binding of said lectin to a chitin where the binding indicates the presence of chitin in the biological sample.

Abstract: This invention provides novel methods for the detection of chitinous contaminants of non-chitinous biological materials. The methods are accurate, highly reproducible, rapid and relatively inexpensive. The methods are well suited to commercial applications, particularly in the food and agriculture industry where biological materials (e.g. food products) are regularly screened for contaminants (e.g. insect, mold, fungus, etc.). In one embodiment, the methods involve contacting a biological sample with a probe that is a lectin that binds chitin, contacting the sample with a pectinase; and detecting binding of said lectin to a chitin where the binding indicates the presence of chitin in the biological sample.